Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients

Abstract

Objective. Vincristine is an important component in the treatment of acute lymphoblastic leukemia (ALL) and is now the backbone of therapy in the induction and consolidation phases of this disease. Proper dosing of vincristine is required to maximize disease control while avoiding toxicity. The gastrointestinal toxicity of vincristine such as decreased peristalsis can potentially be increased if the CYP 3A4 enzyme is inhibited. This interaction may become more prevalent with increasing use of CYP 3A4 inhibitors such as the azole antifungals. Since azoles are increasingly being used for prophylaxis and treatment of fungal infections in this patient population, an assessment of vincristine dosing and toxicity is the first step to constructing guidelines for the coadministration of these agents.

Methods. ALL patients !18 years of age receiving vincristine-based therapy from August 2003 through December 2007 with or without azole therapy were included. Data was collected using electronic patient medical records and the pharmacy system (RxTFC). Information was entered into a database for this retrospective study. Patients were separated into two arms; vincristine with azoles and vincristine only. Patient demographic information, chemotherapy regimen, vincristine-induced symptoms, and concurrent strong CYP 3A4 inhibitors and inducers were collected.

Results. A total of 50 patients received vincristine of which 29 (58%) had concurrent azole therapy. No patients received concurrent major CYP 3A4 inhibitors and the baseline characteristics were similar between groups. Vincristine dosing modifications were more common in the azole group (58.6 vs. 23.8%; p = 0.02). The mean dose reduction of vincristine when combined with an azole was 46.5%. Symptoms of decreased peristalsis were more common in patients receiving azoles (65.5 vs. 28.6%; p = 0.019) and on average occurred after the second vincristine dose. Symptoms occurred in 50, 75, and 66.6% of patients receiving fluconazole, voriconazole, and posaconazole, respectively. Patients were more likely to have an incomplete course of vincristine when receiving azole therapy (48.3 vs. 9.5%; p = 0.004).

Conclusion. Caution should be used with the coadministration of vincristine and azoles. It is recommended that institutional guidelines be developed to standardize care for patients receiving vincristine with azole therapy. Potential measures to avoid this interaction include revisiting azole prophylaxis in this patient group and being judicious in azole selection.

Keywords

leukemia vincristine azoles antifungal CYP3A4

Get full access to this article

View all access options for this article.

References

Linker CA , Levitt LJ , O’Donnell M. et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78(11): 2814-22.

Larson RA , Dodge RK , Burns C. et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85(8): 2025-37.

Kantarjian HM , O’Brien S. , Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Onc 2000; 18(3): 547-61.

Weiss M. , Maslak P. , Feldman E. et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone . J Clin Onc 1996; 14(9): 2480-5.

Schauer P. , Arlin ZA , Mertelsmann R. et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Onc 1983 ; 1(8): 462-70.

McCune JS , Lindley C. Appropriateness of maximum-dose guidelines for vincristine. Am J Health-Syst Pharm 1997 ; 54: 1755-58.

Gubbins PO Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients . Curr Opin Infect Dis 2007; 20: 579-86.

Flockhart DA Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). (Available at http://medicine.iupui.edu/flockhart/table.htm, accessed 12 November 2007).

Cornely OA , Maertens J. , Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4): 348-59.

10.

Cornely OA , Ullmann AJ , Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-72.

11.

Herbrecht R. , Denning DW , Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.

12.

Greenberg RN , Mullane K. , van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-33.

13.

Ullmann AJ , Cornely OA , Burchardt A. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection . Antimicrob Agents Chemother 2006; 50: 658-66.

14.

Chen S. , Wu D. , Sun A. et al. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukemia. Am J Hem 2007; 82: 942.

15.

Takahashi N. , Kameoka Y. , Yamanaka Y. et al. Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Internal Med 2008; 47: 651-53.

16.

Bohme A. , Ganser A. , Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71(6): 311-2.

17.

Frattini M. ‘‘Re: Posaconazole prophylaxis.’’ E-mail to the author , 27 August 2008.

18.

Murayama N. , Imai N. , Nakane T. et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new antifungal agent, in human liver microsomes. Biochem Pharmacol 2007; 73(12): 2020-6.